Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics (NASDAQ: FATE), a clinical-stage biopharmaceutical company focused on iPSC-derived cellular immunotherapies, has granted restricted stock units (RSUs) to two new non-executive employees. The RSUs, representing 30,400 shares of common stock, were approved by the Compensation Committee and granted under the Company's Amended and Restated Inducement Equity Plan. The grants comply with Nasdaq Listing Rule 5635(c)(4) and will vest over four years, with 25% vesting annually, contingent on continued employment.
Fate Therapeutics (NASDAQ: FATE), una società biofarmaceutica in fase clinica specializzata in immunoterapie cellulari derivate da iPSC, ha assegnato unità azionarie vincolate (RSU) a due nuovi dipendenti non esecutivi. Le RSU, che rappresentano 30.400 azioni ordinarie, sono state approvate dal Comitato per la Remunerazione e concesse ai sensi del Piano di Induzione Azionaria Modificato e Ristabilito della Società. Le assegnazioni rispettano la Regola 5635(c)(4) del Nasdaq e matureranno in quattro anni, con il 25% che matura annualmente, subordinato alla continuazione del rapporto di lavoro.
Fate Therapeutics (NASDAQ: FATE), una empresa biofarmacéutica en etapa clínica centrada en inmunoterapias celulares derivadas de iPSC, ha otorgado unidades de acciones restringidas (RSU) a dos nuevos empleados no ejecutivos. Las RSU, que representan 30,400 acciones ordinarias, fueron aprobadas por el Comité de Compensación y otorgadas bajo el Plan de Inducción de Capital Modificado y Restablecido de la Compañía. Las concesiones cumplen con la Regla 5635(c)(4) de Nasdaq y se consolidarán durante cuatro años, con un 25% consolidándose anualmente, condicionado a la continuidad del empleo.
Fate Therapeutics (NASDAQ: FATE)는 iPSC 유래 세포 면역치료제에 중점을 둔 임상 단계 바이오제약 회사로, 두 명의 신규 비임원 직원에게 제한 주식 단위(RSU)를 부여했습니다. 이 RSU는 30,400주의 보통주를 대표하며, 보상 위원회의 승인을 받아 회사의 수정 및 재정비된 유인 주식 계획에 따라 부여되었습니다. 이 부여는 나스닥 상장 규칙 5635(c)(4)를 준수하며, 4년에 걸쳐 점진적으로 권리가 확정되며, 매년 25%씩 확정되며, 계속 고용 조건에 따릅니다.
Fate Therapeutics (NASDAQ : FATE), une société biopharmaceutique en phase clinique spécialisée dans les immunothérapies cellulaires dérivées des iPSC, a attribué des unités d'actions restreintes (RSU) à deux nouveaux employés non exécutifs. Les RSU, représentant 30 400 actions ordinaires, ont été approuvées par le comité de rémunération et attribuées dans le cadre du Plan d'actions incitatives modifié et révisé de la société. Ces attributions sont conformes à la règle 5635(c)(4) du Nasdaq et vestiront sur quatre ans, avec 25 % qui deviendront acquis chaque année, sous réserve de la poursuite de l'emploi.
Fate Therapeutics (NASDAQ: FATE), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf iPSC-abgeleitete zelluläre Immuntherapien spezialisiert hat, hat zwei neuen nicht-exekutiven Mitarbeitern Restricted Stock Units (RSUs) gewährt. Die RSUs, die 30.400 Aktien des Stammkapitals repräsentieren, wurden vom Vergütungsausschuss genehmigt und im Rahmen des geänderten und neu gefassten Anreizaktienplans des Unternehmens gewährt. Die Zuteilungen entsprechen der Nasdaq-Listing-Regel 5635(c)(4) und werden über vier Jahre vesten, wobei jährlich 25 % vesten, abhängig von der fortgesetzten Beschäftigung.
- None.
- None.
SAN DIEGO, May 02, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on May 1, 2025 the Company granted restricted stock units (RSUs) representing 30,400 shares of its common stock to two newly-hired non-executive employees. The grants were approved by the Compensation Committee of the Company’s Board of Directors and granted under the Company’s Amended and Restated Inducement Equity Plan as an inducement material to the new employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with
About Fate Therapeutics, Inc.
Fate Therapeutics is a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases. Using its proprietary iPSC product platform, the Company has established a leadership position in creating multiplexed-engineered iPSC lines and in the manufacture and clinical development of off-the-shelf, iPSC-derived cell products. The Company’s pipeline includes iPSC-derived natural killer (NK) cell and T-cell product candidates, which are selectively designed, incorporate novel synthetic controls of cell function, and are intended to deliver multiple therapeutic mechanisms to patients. Fate Therapeutics is headquartered in San Diego, CA. For more information, please visit www.fatetherapeutics.com.
Contact:
Christina Tartaglia
Precision AQ
212.362.1200
christina.tartaglia@precisionaq.com
FAQ
How many shares of FATE stock were granted as RSUs on May 1, 2025?
What is the vesting schedule for Fate Therapeutics' RSUs granted in May 2025?
Under which rule were FATE's employee inducement awards granted?
What type of company is Fate Therapeutics (FATE)?
